Safety and Effectiveness of Early Aspirin Administration After Mitral Valve Repair

This study compares the efficacy and safety of two different antithrombotic drugs, warfarin and aspirin, in early application after mitral valve repair (MVRep). The objective is to verify whether the type of antithrombotic therapy affects clinical outcomes and the incidence of thromboembolic and bleeding complications within 3 months after MVRep, and to provide safe and effective antithrombotic treatment options for patients undergoing MVRep.

NCT Number	NCT06738992
Lead Sponsor	Guangdong Provincial People's Hospital
Conditions	Mitral Valve Repair Surgery
Enrollment	384 participants
Start Date	2024-11-14
Primary Completion	2027-12-31 (estimated)
Study Completion	2027-12-31 (estimated)
Updated on ClinicalTrials.gov	2024-12-18